⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PVLA News
Palvella Therapeutics, Inc. Common Stock
Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations
globenewswire.com
PVLA
Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
globenewswire.com
PVLA
Form 8-K
sec.gov
PVLA
Palvella Therapeutics Announces Pricing of Upsized Public Offering
globenewswire.com
PVLA
Form 8-K
sec.gov
PVLA
Palvella Therapeutics Announces Proposed Public Offering
globenewswire.com
PVLA
Form 8-K
sec.gov
PVLA
Form 8-K
sec.gov
PVLA
Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
globenewswire.com
PVLA
Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
globenewswire.com
PVLA